Sarepta Therapeutics, Inc. (SRPT) EPS Estimated At $-0.57

June 13, 2018 - By Nicole Peterson

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) LogoInvestors sentiment decreased to 0.97 in Q1 2018. Its down 0.25, from 1.22 in 2017Q4. It worsened, as 31 investors sold Sarepta Therapeutics, Inc. shares while 81 reduced holdings. 45 funds opened positions while 64 raised stakes. 54.74 million shares or 3.52% more from 52.88 million shares in 2017Q4 were reported.
Martingale Asset Mgmt Lp accumulated 10,607 shares. Fincl Architects, New Jersey-based fund reported 205 shares. Dimensional Fund Advsrs Lp holds 111,965 shares or 0% of its portfolio. Dupont Cap Corp owns 0.01% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 5,663 shares. 59,000 are held by State Of Wisconsin Inv Board. Eam Invsts Ltd Liability Company has 0.49% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 39,980 shares. Jabre Capital Prtnrs Sa stated it has 5,900 shares or 0.09% of all its holdings. Bancorporation Of New York Mellon Corp has invested 0.01% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Credit Suisse Ag owns 384,731 shares. Bank Of Montreal Can has 0% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 64,951 shares. Stevens Management Ltd Partnership reported 5,455 shares stake. 1.33M are owned by Jennison Ltd. Amalgamated Bank & Trust owns 8,140 shares. Great West Life Assurance Can, Manitoba – Canada-based fund reported 6,948 shares. Deutsche National Bank & Trust Ag holds 0.04% of its portfolio in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 897,521 shares.

Analysts expect Sarepta Therapeutics, Inc. (NASDAQ:SRPT) to report $-0.57 EPS on July, 18.They anticipate $0.58 EPS change or 50.43 % from last quarter’s $-1.15 EPS. After having $-0.44 EPS previously, Sarepta Therapeutics, Inc.’s analysts see 29.55 % EPS growth. The stock decreased 2.01% or $1.99 during the last trading session, reaching $96.77. About 2.87M shares traded or 131.80% up from the average. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has risen 197.08% since June 14, 2017 and is uptrending. It has outperformed by 184.51% the S&P500.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Ratings Coverage

Among 16 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 14 have Buy rating, 0 Sell and 2 Hold. Therefore 88% are positive. Sarepta Therapeutics had 27 analyst reports since January 3, 2018 according to SRatingsIntel. The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has “Buy” rating given on Monday, March 12 by Piper Jaffray. On Wednesday, January 3 the stock rating was initiated by Janney Capital with “Buy”. Leerink Swann maintained the stock with “Outperform” rating in Tuesday, March 13 report. The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) earned “Buy” rating by Leerink Swann on Tuesday, May 15. Leerink Swann maintained it with “Buy” rating and $77.0 target in Friday, January 19 report. On Tuesday, March 13 the stock rating was maintained by Credit Suisse with “Outperform”. The stock has “Buy” rating by H.C. Wainwright on Monday, March 12. The company was maintained on Wednesday, March 7 by SunTrust. J.P. Morgan maintained the shares of SRPT in report on Wednesday, February 21 with “Buy” rating. Barclays Capital upgraded Sarepta Therapeutics, Inc. (NASDAQ:SRPT) on Friday, May 11 to “Overweight” rating.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA therapeutics for the treatment of rare neuromuscular diseases. The company has market cap of $6.34 billion. The firm offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy , which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It currently has negative earnings. It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD.

More notable recent Sarepta Therapeutics, Inc. (NASDAQ:SRPT) news were published by: Seekingalpha.com which released: “Wave Life Sciences: What’s Cooking Behind This Innovator?” on May 23, 2018, also Nasdaq.com with their article: “Sarepta Therapeutics to Present at Two Upcoming Investor Conferences” published on June 05, 2018, Nasdaq.com published: “Sarepta Therapeutics Enters into Long-term Strategic Manufacturing Partnership with Brammer Bio to Support Gene …” on June 13, 2018. More interesting news about Sarepta Therapeutics, Inc. (NASDAQ:SRPT) were released by: Investorplace.com and their article: “7 Strong Buy Stocks Analysts Are Upgrading Now, Including Facebook, Inc.” published on June 13, 2018 as well as Bizjournals.com‘s news article titled: “Biogen’s head of late-stage trials leaves for Sarepta” with publication date: June 07, 2018.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.